Metastatic colorectal cancer (mCRC) remains a major clinical challenge due to heterogeneous treatment responses and the development of therapeutic resistance. Current tissue-based molecular profiling is limited by invasiveness and the inability to enable longitudinal monitoring. Extracellular vesicles (EVs) represent a promising source of non-invasive biomarkers, carrying stable RNA and proteins reflective of tumor biology. This study aims to identify and validate EV-derived transcriptomic and proteomic biomarkers to monitor disease evolution, predict treatment response, and support personalized management of patients with mCRC.
Age ≥ 18 years;
Histologically confirmed diagnosis of colorectal adenocarcinoma;
Radiological evidence of metastatic or locally advanced unresectable disease;
First-line treatment for metastatic disease already completed or ongoing according to standard clinical practice;
Absence of suitable biological samples or samples unsuitable for molecular analyses;
Incomplete clinical data preventing the performance of the planned analyses;
Insufficient quality of stored biological samples for the assessment of EV-RNA and EV-PROT analyses.
Age ≥ 18 years;